1.
Fassbender K, Mossner R, Motsch L, Kischka U, Grau A, Hennerici M. Circulating selectin- and immunoglobulin-type adhesion molecules in acute ischemic stroke. Stroke 1995; 26:1361–4.CrossrefGoogle Scholar
2.
Aoki T, Sumii T, Mori T, Wang X, Lo EH. Blood-brain barrier disruption and matrix metalloproteinase-9 expression during reperfusion injury: mechanical versus embolic focal ischemia in spontaneously hypertensive rats. Stroke 2002; 33:2711–7.CrossrefGoogle Scholar
3.
Wagner S, Nagel S, Kluge B, Schwab S, Heiland S, Koziol J, et al. Topographically graded postischemic presence of metalloproteinases is inhibited by hypothermia. Brain Res 2003; 984:63–75.Google Scholar
4.
Alvarez B, Ruiz C, Chacon P, Alvarez-Sabin J, Matas M. Serum values of metalloproteinase-2 and metalloproteinase-9 as related to unstable plaque and inflammatory cells in patients with greater than 70% carotid artery stenosis. J Vasc Surg 2004; 40:469–75.CrossrefGoogle Scholar
5.
Beaudeux J-L, Giral F, Bruckert E, Foglietti M-J, Chapman J. Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives. Clin Chem Lab Med 2004; 42:121–31.CrossrefGoogle Scholar
6.
Loftus IM, Naylor AR, Goodall S, Crowther M, Jones L, Bell PR, et al. Increased matrix metalloproteinase-9 activity in unstable carotid plaques: a potential role in acute plaque disruption. Stroke 2000; 31:40–7.CrossrefGoogle Scholar
7.
Rosenberg GA, Estrada EY, Dencoff JE. MMPs and TIMPs are associated with BBB opening after reperfusion in rat brain. Stroke 1998; 29:2189–95.CrossrefGoogle Scholar
8.
Sumii T, Lo EH. Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke 2002; 33:831–6.CrossrefGoogle Scholar
9.
Montaner J, Alvarez-Sabin J, Molina C, Angles A, Abilleira S, Arenillas J, et al. Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke 2001; 32:1759–66.CrossrefGoogle Scholar
10.
Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991; 337:1521–6.Google Scholar
11.
NSA Stroke Prevention Guidelines. A review of guidelines and a multidisciplinary consensus statement from the National Stroke Association. J Am Med Assoc 1999;281:24–31.Google Scholar
12.
Mead GE, Lewis SC, Wardlaw JM, Dennis MS, Warlow CP. How well does the Oxfordshire community stroke project classification predict the site and size of the infarct on brain imaging? J Neurol Neurosurg Psychiatry 2000; 68:558–62.CrossrefGoogle Scholar
13.
Birkedal-Hansen H. Proteolytic remodeling of extracellular matrix. Curr Opin Cell Biol 1995; 7:728–35.CrossrefGoogle Scholar
14.
Romanic AM, White RF, Arleth AJ, Ohlstein EH, Barone FC. MMP expression increases after cerebral focal ischemia in rats: inhibition of MMP-9 reduces infarct size. Stroke 1998; 29:1020–30.CrossrefGoogle Scholar
15.
Asahi M, Wang X, Mori T, Sumii T, Jung JC, Moskowitz MA, et al. Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci 2001; 21:7724–32.Google Scholar
16.
Asahi M, Sumii T, Fini ME, Itohara S, Lo EH. Matrix metalloproteinase 2 gene knockout has no effect on acute brain injury after focal ischemia. Neuroreport 2001; 12:3003–7.Google Scholar
17.
Horstmann S, Kalb P, Koziol J, Gardner H, Wagner S. Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies. Stroke 2003; 34:2165–70.CrossrefGoogle Scholar
18.
Lorenzl S, De Pasquale G, Segal AZ, Beal MF. Dysregulation of the levels of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the early phase of cerebral ischemia. Stroke 2003; 34:e37–8.CrossrefGoogle Scholar
19.
Castellanos M, Leira R, Serena J, Pumar JM, Lizasoain I, Castillo J, et al. Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke 2003; 34:40–6.CrossrefGoogle Scholar
20.
Clark AW, Krekoski CA, Bou SS, Chapman KR, Edwards DR. Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia. Neurosci Lett 1997; 238:53–6.Google Scholar
21.
Kuzuya M, Kanda S, Sasaki T, Tamaya-Mori N, Cheng XW, Itoh T, et al. Deficiency of gelatinase a suppresses smooth muscle cell invasion and development of experimental intimal hyperplasia. Circulation 2003; 108:1375–81.CrossrefGoogle Scholar
22.
Montaner J, Alvarez-Sabín J, Molina CA, Anglés A, Abilleira S, Arenillas J, et al. Matrix metalloproteinase (MMP-9) expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke 2001; 32:2762–7.CrossrefGoogle Scholar
23.
Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribó M, et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 2003; 107:598–603.CrossrefGoogle Scholar
24.
Alvarez-Sabin J, Delgado P, Abilleira S, Molina CA, Arenillas J, Ribó M, et al. Temporal profile of matrix metalloproteinases and their inhibitors after spontaneous intracerebral hemorrhage: relationship to clinical and radiological outcome. Stroke 2004; 35:1316–22.CrossrefGoogle Scholar
25.
Van den Steen PE, Dubois B, Nelissen I, Rudd PM, Dwek RA, Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol 2002; 37:375–536.Google Scholar
26.
Montaner J, Rovira A, Molina CA, Arenillas JF, Ribó M, Chacon P, et al. Plasmatic level of neuroinflammatory markers predict the extent of diffusion-weighted image lesions in hyperacute stroke. J Cereb Blood Flow Metab 2003; 23:1403–7.Google Scholar
27.
Rosell A, Alvarez-Sabin J, Arenillas JF, Rovira A, Delgado P, Fernandez-Cadenas I, et al. A matrix metalloproteinase protein array reveals a strong relation between MMP-9 and MMP-13 with diffusion-weighted image lesion increase in human stroke. Stroke 2005; 36:1415–20.CrossrefGoogle Scholar
28.
Lee SR, Tsuji K, Lee SR, Lo EH. Role of matrix metalloproteinases in delayed neuronal damage after transient global cerebral ischemia. J Neurosci 2004; 24:671–8.CrossrefGoogle Scholar
29.
Avolio C, Ruggieri M, Giuliani F, Liuzzi GM, Leante R, Riccio P, et al. Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes. J Neuroimmunol 2003; 136:46–53.Google Scholar
30.
McGirt MJ, Lynch JR, Blessing R, Warner DS, Friedman AH, Laskowitz DT. Serum von Willebrand factor, matrix metalloproteinase-9, and vascular endothelial growth factor levels predict the onset of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Neurosurgery 2002; 51:1128–34 [discussion 1134–5].CrossrefGoogle Scholar
31.
Dubois B, Leary SM, Nelissen I, Opdenakker G, Giovannoni G, Thompson AJ. Serum gelatinase B/MMP-9 in primary progressive multiple sclerosis patients treated with interferon-beta-1a. J Neurol 2003; 250:1037–43.Google Scholar
32.
Correale J, de los Milagros Bassani Molinas M. Temporal variations of adhesion molecules and matrix metalloproteinases in the course of MS. J Neuroimmunol 2003; 140:198–209.CrossrefGoogle Scholar
33.
Kuyvenhoven JP, Ringers J, Verspaget HW, Lamers CB, van Hoek B. Serum matrix metalloproteinase MMP-2 and MMP-9 in the late phase of ischemia and reperfusion injury in human orthotopic liver transplantation. Transplant Proc 2003; 35:2967–9.CrossrefGoogle Scholar
34.
Sfiridaki A, Miyakis S, Tsirakis G, Alegakis A, Passam AM, Kandidaki E, et al. Systemic levels of interleukin-6 and matrix metalloproteinase-9 in patients with multiple myeloma may be useful as prognostic indexes of bone disease. Clin Chem Lab Med 2005; 43:934–8.Google Scholar
35.
Jung K, Lein M, Laube C, Lichtinghagen R. Blood specimen collection methods influence the concentration and the diagnostic validity of matrix metalloproteinase 9 in blood. Clin Chim Acta 2001; 314:241–4.Google Scholar
36.
Alby C, Ben Abdesselam O, Foglietti MJ, Beaudeux JL. Preanalytical aspects regarding the measurement of metalloproteinase-9 and tissue inhibitor or metalloproteinase-1 in blood. Clin Chim Acta 2002; 325:183–6.Google Scholar
Comments (0)